恶性葡萄胎患者血清Hcy和MMP-2、TIMP-2检测的临床评价
Clinical Evaluation of Determination the Changes on Serum Hcy and MMP-2,TIMP-2 Levels in Patients with Malignant Hydatidiform Mole
陆瑞 1李兰亚 1徐发林1
作者信息
摘要
目的:评估了恶性葡萄胎患者化疗前后血清Hcy和MMP-2、TIMP-2水平的变化及临床意义.方法:应用酶免法和放射免疫分析对32例恶性葡萄胎患者进行了化疗前后血清Hcy和MMP-2、TIMP检测,并与35名正常妇女作比较.结果:恶性葡萄胎患者在化疗前血清Hcy和MMP-2、TIMP-2水平均非常显著地高于正常妇女组(P<0.01),化疗后6个月未复发的29例中其水平明显下降或接近正常,而复发的3例,其水平又回升到化疗前水平(P<0.01).结论:检测恶性葡萄胎患者血清Hcy和MMP-2、TIMP-2水平的变化可作为患者诊断和疗效观察的参考.
Abstract
Objective To assess the clinical evaluation of serum Hey and MMP-2, TIMP-2 levels both before and after chemotherapy in patients with malignant hydatidiform mole. Methods Serum Hey (with ELISA), Serum MMP-2, TIMP-2(with RIA) levels were determined 32 patients with malignant hydatidiform mole and compared with 35 normal parsons served as control. Results Before chemotherapy serum Hey and MMP-2, TIMP-2 levels in the patients were significantly higher than those in controls (P<0.01),6 months after chemotherapy the levels in 29 cases without recurrence remained dropping markedly and approached those in controls. However, in 3 patients with recurrence the levels increased again and approached the former chemotherapy. Conclusion Detection of serum Hey and MMP-2, TIMP-2 levels might be a useful reference for diagnose and therapeutic efficacy in patients with malignant hydalidiform mole.
关键词
恶性葡萄胎/同型半胱氨酸/基质金属蛋白酶-2/金属蛋白酶组织抑制因子Key words
malignant hydatidiform mole/homocysteine(Hcy)/matrix metallo proteimare-2(MMP-2)/tissue inhibitors melallo proteimare-2 (TIMP-2)引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据